10-Q: Global Technologies Q1 2026 Revenue Plunges Amid Strategic Shift

Global Technologies reported a significant revenue decline in Q1 2026, driven by a strategic shift in its health and wellness operations and the termination of its EV charging station acquisition.

Summary

• Net income decreased by 36.69% to $166,199 for the three months ended September 30, 2025, down from $262,547 in the prior year period.
• Revenue plummeted by 70.82% to $195,325 for the three months ended September 30, 2025, compared to $669,431 in the prior year period.
• Gross profit saw a sharp decline of 79.70% to $96,928 for the three months ended September 30, 2025.
• Operating activities shifted from providing $217,114 cash in the three months ended September 30, 2024, to using $115,031 cash in the three months ended September 30, 2025.
• The company terminated its acquisition of GOe3, LLC (an EV charging station entity) on June 30, 2025, due to unmet operational and financial milestones.
• A strategic shift in Primecare Supply, LLC's operating focus from a wholesale model to a direct-to-clinic sales strategy is expected to result in slower near-term revenue growth but improved margins and long-term value.
• Issued 200,000 shares of Series P Preferred Stock for $200,000 cash on August 24, 2025, with holders entitled to a 5% revenue share from Primecare Supply, LLC and GTLL Advisory Group, LLC until 200% of their original investment is received.
• Disclosure controls and procedures were deemed ineffective as of September 30, 2025, due to resource constraints and material weaknesses, including a lack of sufficient GAAP-knowledgeable personnel and the absence of an audit committee.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including a substantial revenue decline, operating losses, and a 'going concern' warning. While strategic shifts and a gain on derivative liability offer some positives, the overall financial health and internal control weaknesses indicate a high-risk profile.

Positives

• Cash and cash equivalents increased by 124.6% from $68,108 at June 30, 2025, to $152,977 at September 30, 2025.
• Total liabilities decreased by 22.7% from $1,221,387 at June 30, 2025, to $944,278 at September 30, 2025.
• A significant gain on derivative liability of $282,000 was recognized for the three months ended September 30, 2025.
• The company successfully raised $200,000 through the issuance of Series P Preferred Stock.
• A related party loan of $100 was repaid during the period.
• The strategic shift in Primecare Supply's sales model is intended to generate more sustainable revenue, improved margins, and stronger free cash flow in the long term.
• The termination of the GOe3 acquisition allowed for the reallocation of resources to core health technology, procurement, and strategic advisory services.

Negatives

• Revenue decreased by 70.82% to $195,325 for the three months ended September 30, 2025, compared to $669,431 in the prior year.
• Gross profit decreased by 79.70% to $96,928 for the three months ended September 30, 2025, from $477,542 in the prior year.
• Operating activities used $115,031 in cash for the three months ended September 30, 2025, a significant decline from $217,114 provided in the same period last year.
• The company reported an operating loss of $108,214 for the three months ended September 30, 2025, compared to an operating income of $272,642 in the prior year.
• Officers and directors compensation increased by 276.84% to $94,209 for the three months ended September 30, 2025.
• The company has an accumulated deficit of $167,389,438 as of September 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern due to a history of net losses and negative operating cash flows.
• Disclosure controls and procedures were deemed ineffective due to material weaknesses, including insufficient GAAP-knowledgeable personnel, lack of an audit committee, and no independent directors.
• 10 Fold Services, LLC ceased procurement operations due to changes in FDA regulations regarding GLP-1 products.
• One customer accounted for 100% of revenues for the three months ended September 30, 2025 and 2024, indicating high customer concentration risk.

Risks

• Substantial doubt about the ability to continue as a going concern due to a history of net losses and negative cash flows from operations.
• Reliance on securing additional funding sources, such as corporate partnerships, licensing agreements, convertible debentures, or equity securities, with no assurance of availability or attractive terms.
• Potential significant dilutive effect on existing shareholders if additional capital is raised through equity issuance.
• Ineffective disclosure controls and procedures due to resource constraints, lack of sufficient GAAP-knowledgeable personnel, absence of an audit committee, and no independent outside directors.
• High concentration of revenue from a single customer (100% for the reported periods).
• Dependence on two pharmaceutical compounding companies as primary suppliers.
• Risks associated with the ability to effectively execute the business plan, manage expansion and growth, protect brands, repay debts, and rely on third-party suppliers outside of the United States.
• Risks in connection with completed or potential acquisitions, dispositions, and other strategic growth opportunities and initiatives, including integration risks.
• Uncertainties related to general economic conditions, inflation, rising interest rates, lower consumer confidence, volatile capital markets, supply chain disruptions, and geopolitical conflicts.
• The company's business model is subject to risks inherent in establishing new business plans through its operating subsidiaries.

Future Outlook

Management expects GTLL Advisory Group to commence revenue-generating operations in fiscal year 2026. The strategic shift in Primecare Supply's sales model is anticipated to result in slower near-term revenue growth but is designed to generate more sustainable revenue, improved margins, stronger free cash flow, and long-term shareholder value as sales volumes scale and mature. The company plans to secure additional funding through corporate partnerships, licensing agreements, convertible debentures, and equity securities to address going concern uncertainties.

Management Comments

• "Management believes Primecare Supply represents a core growth engine for Global Technologies, Ltd., offering scalable infrastructure, recurring transaction-based revenue, and a technology-enabled compliance advantage in the expanding health and wellness market."
• "Management believes this transition [in Primecare Supply's sales model] will result in slower near-term revenue growth but is designed to generate more sustainable revenue, improved margins, stronger free cash flow, and long-term shareholder value as sales volumes scale and mature."
• "Management believes the decision to unwind the [GOe3] acquisition allowed Global to reallocate resources toward its core business segments in health technology, procurement, and strategic advisory services."
• "Management expects GTLL Advisory to commence revenue-generating operations in fiscal year 2026 as part of Globals expanding health-technology and advisory services portfolio."
• "We have therefore concluded there is substantial doubt about our ability to continue as a going concern."

Industry Context

Global Technologies is navigating a dynamic health and wellness industry, particularly in pharmaceutical supply chain and advisory services. The company's strategic shift in Primecare Supply's model, moving from wholesale to direct-to-clinic sales, reflects an adaptation to evolving FDA regulatory requirements, specifically impacting GLP-1 products. This move aims to gain better control over client relationships, data, and supply chains, potentially positioning it for more resilient growth in a competitive market. The termination of the EV charging station venture (GOe3) indicates a refocusing on its core health technology and advisory segments, aligning with broader trends of specialization and leveraging technology for operational efficiency in healthcare.

Comparison to Industry Standards

• The filing does not provide specific industry benchmarks or comparable company data to assess the results against global standards.
• The significant revenue decline and shift to an operating loss suggest underperformance relative to a growth-oriented health technology sector, even considering the strategic transition.
• The high customer concentration (100% from one customer) is a notable deviation from best practices for diversified revenue streams in most industries.

Management Changes

Corporate Governance

Related Party Transactions

• Loans payable to officers/directors were reduced from $100 to $0 during the period.
• Convertible Promissory Notes totaling $300,000 are payable to Tri-Bridge Ventures, LLC, with accrued interest of $37,479 and $74,959 respectively, as of September 30, 2025.
• H. Wyatt Flippen, CEO, received 125,000 shares of Series N Preferred Stock in connection with his employment agreement.

Stakeholder Impact

• Shareholders: Potential for significant dilution if future capital raises involve equity. The "going concern" warning and ineffective internal controls pose substantial risks to investment value. Revenue share for Series P Preferred Stock holders could impact common shareholder returns.
• Employees: New management appointment (Fredrick K. Cutcher) for Primecare Supply indicates growth in that subsidiary.
• Customers: Primecare Supply's shift to direct-to-clinic sales aims to improve client relationships and service.
• Creditors: The "going concern" warning and reliance on future funding sources indicate elevated risk for existing creditors.

Next Steps

• GTLL Advisory Group, LLC is expected to commence revenue-generating operations in fiscal year 2026.
• Management plans to secure additional funding sources, including corporate partnerships, licensing agreements, convertible debentures, and equity securities, to address going concern uncertainties.
• The Board is seeking to improve internal controls and procedures to remediate identified material weaknesses.
• Primecare Supply, LLC will continue to scale and mature its direct-to-clinic sales volumes.

Key Dates

Recommendation

The company's Q1 2026 results show a drastic 70.82% revenue decline and a shift from operating income to a significant operating loss. While a gain on derivative liability boosted net income, this is non-operational and masks underlying business weakness. The explicit 'going concern' warning, coupled with ineffective internal controls, a history of net losses, and negative operating cash flow, signals severe financial distress and high operational risk. The high customer concentration (100% from one customer) further exacerbates risk. Despite a strategic shift intended for long-term value, the immediate financial deterioration and governance issues make the stock a 'strong sell' for seasoned investors.

Keywords

Global Technologies, GTLL, SEC Filing, 10-Q, Quarterly Report, Healthcare Technology, Wellness Industry, Pharmaceutical Supply Chain, Primecare Supply, GTLL Advisory Group, Sinq Ops, Corporate Governance, Financial Performance, Going Concern, Derivative Liability, Preferred Stock, Strategic Shift, FDA Regulations, GLP-1, EV Charging Stations